Literature DB >> 19072283

Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Joshua B Owen1, Fabio Di Domenico, Rukhsana Sultana, Marzia Perluigi, Chiara Cini, William M Pierce, D Allan Butterfield.   

Abstract

Alzheimer's disease (AD) is the most common type of dementia, comprising 60-80% of all reported cases, and currently affects 5.2 million Americans. AD is characterized pathologically by the accumulation of senile plaques (SPs), neurofibrillary tangles (NFTs), and synapse loss. The early stages of memory loss associated with AD have been studied in a condition known as amnestic mild cognitive impairment (MCI), arguably the earliest form of AD. In spite of extensive research across a variety of disciplines, the cause of AD remains elusive. Proteomics techniques have helped to advance knowledge about AD by identifying irregularities in protein expression and post-translational modifications (PTMs) in AD brain. Glycosylation is a less studied PTM with regards to AD and MCI. This PTM is important to study because glycosylation is involved in proper protein folding, protein anchoring to cell membranes, and the delivery of proteins to organelles, and these processes are impaired in AD. Concanavalin-A (Con-A) binds to N-linked glycoproteins, but hydrophobic sites on nonglycoproteins are also known to bind Con-A. To our knowledge, the present study is the first to examine Con-A-associated brain proteins in MCI and AD with focus on the hippocampus and inferior parietal lobule (IPL) brain regions. Proteins found in AD hippocampus with altered levels are glutamate dehydrogenase (GDH), glial fibrillary acidic protein (GFAP), tropomyosin 3 (TPM3), Rab GDP-dissociation inhibitor XAP-4 (XAP4), and heat shock protein 90 (HSP90). Proteins found with altered levels in AD IPL are alpha-enolase, gamma-enolase, and XAP-4. MCI hippocampal proteins with altered levels are dihydropyrimidase-2 (DRP2), glucose-regulated protein 78 (GRP-78), protein phosphatase related protein Sds-22 (Sds22), and GFAP and the only protein found with altered levels in MCI IPL was beta-synuclein. These results are discussed with reference to biochemical and pathological alterations in and progression of AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072283      PMCID: PMC2658606          DOI: 10.1021/pr800667a

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  104 in total

1.  Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease.

Authors:  D Boyd-Kimball; R Sultana; H Fai Poon; B C Lynn; F Casamenti; G Pepeu; J B Klein; D A Butterfield
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

2.  Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease.

Authors:  Debra Boyd-Kimball; Alessandra Castegna; Rukhsana Sultana; H Fai Poon; Robin Petroze; Bert C Lynn; Jon B Klein; D Allan Butterfield
Journal:  Brain Res       Date:  2005-04-15       Impact factor: 3.252

3.  Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid.

Authors:  Yuko Ogata; M Cristine Charlesworth; David C Muddiman
Journal:  J Proteome Res       Date:  2005 May-Jun       Impact factor: 4.466

4.  A study of glycoproteins in human serum and plasma reference standards (HUPO) using multilectin affinity chromatography coupled with RPLC-MS/MS.

Authors:  Ziping Yang; William S Hancock; Tori Richmond Chew; Leo Bonilla
Journal:  Proteomics       Date:  2005-08       Impact factor: 3.984

5.  Proteomic identification of differentially expressed proteins in the aging murine olfactory system and transcriptional analysis of the associated genes.

Authors:  H Fai Poon; Radhika A Vaishnav; D Allan Butterfield; Marilyn L Getchell; Thomas V Getchell
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

6.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; David G Camp; Matthew E Monroe; Ronald J Moore; Richard D Smith
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

7.  The unfolded protein response is activated in Alzheimer's disease.

Authors:  J J M Hoozemans; R Veerhuis; E S Van Haastert; J M Rozemuller; F Baas; P Eikelenboom; W Scheper
Journal:  Acta Neuropathol       Date:  2005-06-23       Impact factor: 17.088

8.  Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain.

Authors:  Minna A Korolainen; Seppo Auriola; Tuula A Nyman; Irina Alafuzoff; Tuula Pirttilä
Journal:  Neurobiol Dis       Date:  2005-06-27       Impact factor: 5.996

Review 9.  Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases.

Authors:  Dennis J Selkoe
Journal:  Nat Cell Biol       Date:  2004-11       Impact factor: 28.824

10.  Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis.

Authors:  Marzia Perluigi; H Fai Poon; Kenneth Hensley; William M Pierce; Jon B Klein; Vittorio Calabrese; Carlo De Marco; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2005-04-01       Impact factor: 7.376

View more
  35 in total

Review 1.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

3.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

4.  Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures.

Authors:  Kenneth Hensley; Alexandar Christov; Shekhar Kamat; X Cai Zhang; Kenneth W Jackson; Stephen Snow; Jan Post
Journal:  J Neurosci       Date:  2010-02-24       Impact factor: 6.167

5.  Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-β peptide of amyloid precursor protein.

Authors:  R A S Robinson; M B Lange; R Sultana; V Galvan; J Fombonne; O Gorostiza; J Zhang; G Warrier; J Cai; W M Pierce; D E Bredesen; D A Butterfield
Journal:  Neuroscience       Date:  2011-01-09       Impact factor: 3.590

Review 6.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

7.  Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age.

Authors:  Rukhsana Sultana; Renã A S Robinson; Fabio Di Domenico; Hafiz Mohmmad Abdul; Daret K St Clair; William R Markesbery; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-06-25       Impact factor: 4.044

Review 8.  Actin regulation by tropomodulin and tropomyosin in neuronal morphogenesis and function.

Authors:  Kevin T Gray; Alla S Kostyukova; Thomas Fath
Journal:  Mol Cell Neurosci       Date:  2017-04-19       Impact factor: 4.314

Review 9.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

10.  Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease.

Authors:  Jennifer L Furman; Diana M Sama; John C Gant; Tina L Beckett; M Paul Murphy; Adam D Bachstetter; Linda J Van Eldik; Christopher M Norris
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.